Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Drug Overdose – Pipeline Review, H1 2017, provides an overview of the Drug Overdose (Toxicology) pipeline landscape.
Drug overdoses occur when a person takes more than the medically recommended dose of a prescription or over-the-counter drug. It can be either accidental or intentional. Symptoms include sleepiness, confusion, chest pain, seizures, abdominal pain, nausea, vomiting, and diarrhea. Risk factors include age, gender, mental illness and history of overdose. Treatment includes antidote and activated charcoal.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Drug Overdose – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Drug Overdose (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Drug Overdose (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Drug Overdose and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 1, 1, 1, 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Drug Overdose (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Drug Overdose (Toxicology).
- The pipeline guide reviews pipeline therapeutics for Drug Overdose (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Drug Overdose (Toxicology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Drug Overdose (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Drug Overdose (Toxicology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Drug Overdose (Toxicology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Drug Overdose (Toxicology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Fab'entech SA
INSYS Therapeutics Inc
Klaria Pharma Holding AB
Opiant Pharmaceuticals Inc
Ventria Bioscience
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Drug Overdose – Overview
Drug Overdose – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Drug Overdose – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Overdose – Companies Involved in Therapeutics Development
Fab'entech SA
INSYS Therapeutics Inc
Klaria Pharma Holding AB
Opiant Pharmaceuticals Inc
Ventria Bioscience
Drug Overdose – Drug Profiles
FBT-001 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KL-00514 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
melatonin – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naloxone hydrochloride – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naloxone hydrochloride – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naloxone hydrochloride – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naloxone hydrochloride – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Drug Overdose – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Drug Overdose – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VEN-100 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug Overdose – Dormant Projects
Drug Overdose – Discontinued Products
Drug Overdose – Product Development Milestones
Featured News & Press Releases
Mar 16, 2017: New Data Presented on Adapt Pharmas Community Use of Narcan Nasal Spray 4 mg to Reverse Opioid-Related Overdose
Mar 15, 2017: Mucodel Pharma Announces Patent Allowance for Mucodel’s Co-Gel Buccal Naloxone (Exonal)
Mar 09, 2017: Opiant Pharmaceuticals Announces FDA Orange Book Listings for Two New NARCAN Nasal Spray Patents
Feb 28, 2017: Adapt Pharma Marks One-Year Anniversary of NARCAN Nasal Spray (naloxone HCl) 4mg Launch in the U.S.
Feb 21, 2017: Adapt Pharma Announces European Marketing Application Filed For Naloxone Hydrochloride Nasal Spray
Jan 30, 2017: Kroger Pharmacies to Increase Access to Naloxone in North Texas, East Texas and Southeast Texas
Jan 11, 2017: Opiant Pharmaceuticals Announces 2017 Corporate and Clinical Goals
Jan 09, 2017: Opiant Pharmaceuticals Featured in Recent Media Highlighting NARCAN Nasal Spray and Heroin Vaccine Development
Nov 22, 2016: Adapt Pharma Welcomes U.S. Food and Drug Administration Consumer Update Regarding Opioids
Oct 27, 2016: Opiant Pharmaceuticals Announces FDA Orange Book Listing for Narcan Nasal Spray Patent
Oct 06, 2016: FDA Joint Meeting Endorses Commitment to Higher Doses and Broader Access for Naloxone to Help in Fight Against Opioid Overdose
Oct 05, 2016: Adapt Pharma Announces NARCAN coverage with California Medi-Cal Program
Oct 03, 2016: Health Canada Approves Adapt Pharmas Naloxone Hydrochloride Nasal Spray to Treat Opioid Overdose
Sep 20, 2016: Newly Published Study Finds NARCAN Nasal Spray Concentrated Formulation Rapidly Delivers an Effective Naloxone Dose and is Readily Usable by the General Public
Jul 12, 2016: Adapt Pharma to Launch Program to Raise Awareness, Expand Access and Facilitate Product Experience of NARCAN (Naloxone HCl) Nasal Spray - a new Treatment for Opioid Overdose
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Drug Overdose, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Drug Overdose – Pipeline by Fab'entech SA, H1 2017
Drug Overdose – Pipeline by INSYS Therapeutics Inc, H1 2017
Drug Overdose – Pipeline by Klaria Pharma Holding AB, H1 2017
Drug Overdose – Pipeline by Opiant Pharmaceuticals Inc, H1 2017
Drug Overdose – Pipeline by Ventria Bioscience, H1 2017
Drug Overdose – Dormant Projects, H1 2017
Drug Overdose – Discontinued Products, H1 2017
List of Figures
Number of Products under Development for Drug Overdose, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017
